Almirall and BSC: A New Era in Dermatological Research
In a significant move to enhance medical dermatology, Almirall, S.A., a global biopharmaceutical company, has announced an expanded collaboration with the Barcelona Supercomputing Center (BSC). This strategic framework agreement aims to deepen their long-standing partnership by leveraging cutting-edge technologies such as Artificial Intelligence (AI) and High-Performance Computing (HPC). The goal? To identify new opportunities for collaboration in discovering innovative therapies for skin diseases.
Strengthening Public-Private Collaboration
As part of this enhanced partnership, Almirall will join the ‘BSC Connects’ program, a strategic initiative designed to foster public-private collaboration. This program aims to bridge the gap between advanced scientific knowledge and industry leaders, providing Almirall with access to personalized training and state-of-the-art technologies. By participating in this initiative, Almirall will be better equipped to co-develop innovative R&D projects through 2026, ultimately benefiting patients with skin conditions.
Innovation at the Core of Almirall’s Strategy
This alliance is not just a partnership; it represents a key pillar in Almirall’s innovation strategy. By integrating disruptive technologies into its research and development pipeline, Almirall aims to accelerate the creation of advanced dermatological treatments. The collaboration builds on previous successful R&D projects and is framed within a broader research collaboration between BSC and Almirall. This synergy is expected to drive the identification of innovative technologies with high-impact potential, addressing complex dermatological challenges.
Empowering Research and Development
The collaboration empowers professionals from both institutions to tackle pressing research challenges in dermatology. By capitalizing on the scientific expertise of BSC and Almirall, the BSC Connects framework will facilitate direct collaboration on scientific topics of mutual interest. These topics range from genomics to digital twins and drug design, creating a fertile ground for innovation.
Dr. Karl Ziegelbauer, Chief Scientific Officer at Almirall, emphasized the importance of this collaboration, stating, “Our passion for medical dermatology drives us to constantly seek innovative solutions that can make a real difference in patients’ lives.” He highlighted that combining BSC’s expertise in supercomputing and AI with Almirall’s deep understanding of dermatology creates a powerful synergy aimed at accelerating the development of the next generation of skin treatments.
BSC Connects: Bridging Science and Industry
The ‘BSC Connects’ initiative is designed to drive public-private collaboration and accelerate knowledge transfer between science and industry. It enables companies and institutions to access BSC’s scientific expertise, technology, and supercomputing capabilities. This includes specialized training, the development of use cases, and opportunities for collaboration on European projects.
The program offers a structured approach that spans from identifying technological challenges to evaluating and optimizing results. It acts as a bridge between BSC’s scientific talent and the innovation ecosystem, facilitating the development of high-impact strategic projects.
The Role of BSC in European Supercomputing
BSC is a leading international research center and a key player in the European supercomputing infrastructure. Home to one of the world’s most powerful supercomputers, MareNostrum 5, BSC specializes in HPC and AI. Its dual role involves providing supercomputing infrastructure and services to Spanish and European scientists while generating knowledge and technology for societal benefit.
Mateo Valero, Director of BSC, remarked on the significance of the agreement with Almirall, stating, “This agreement within the framework of the BSC Connects program is an example of how supercomputing and artificial intelligence can be placed at the service of industry to generate a real impact on people’s health.” This vision of collaboration underscores the potential of technology as a driver of innovation in medical dermatology.
About Almirall and BSC
Almirall is dedicated to transforming the lives of patients through innovative medical dermatology solutions. Founded in 1944 and headquartered in Barcelona, the company collaborates closely with leading scientists and healthcare professionals to deliver groundbreaking treatments. With a presence in over 100 countries, Almirall continues to improve the lives of patients globally.
On the other hand, BSC is committed to advancing research in various fields, including life sciences, Earth sciences, and computational social sciences. The center plays a crucial role in managing the Spanish Supercomputing Network and is a key player in the EuroHPC initiative, which aims to enhance HPC capabilities across Europe.
Looking Ahead
The partnership between Almirall and BSC marks a pivotal moment in the quest for innovative dermatological treatments. By harnessing the power of AI and supercomputing, both organizations are poised to make significant strides in addressing the needs of patients with skin diseases. This collaboration not only reflects a commitment to scientific advancement but also highlights the importance of integrating technology into healthcare for the benefit of society.
